Growth Hormone Deficiency (GHD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Growth Hormone Deficiency (GHD) Market Outlook

Thelansis’s “Growth Hormone Deficiency (GHD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Growth Hormone Deficiency treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Growth Hormone Deficiency (GHD) Overview

Growth Hormone Deficiency (GHD) is a medical condition that arises due to issues in the pituitary gland, leading to a lack of Growth Hormone (GH) production. This condition is typically observed in children, causing growth failure and short stature. GHD can be categorized into two main types: genetic GH deficiency, which involves identifiable genetic mutations like GH-1, GHRHR, and PROP-1, and idiopathic GH deficiency, where no specific genetic anomaly can be pinpointed. In cases of idiopathic GH deficiency, the pituitary gland is often smaller, and there's evidence of abnormalities in the pituitary stalk or the posterior lobe being in an abnormal position. The primary indicator of growth hormone deficiency is a deceleration or halt in growth starting around the age of two or three. This concern might emerge through regular growth chart monitoring or become evident when a child joins school and is notably shorter than their peers. Diagnosis of growth hormone deficiency involves blood tests to measure hormone levels and diligent tracking of height using standardized growth charts that compare a child's height to the average for their age and gender. Severe congenital GHD in infants might not immediately exhibit signs of slow growth; instead, they could mainly present low blood sugar levels. For adults with significant GHD, certain effects might be observed:

1. Redistribution of body fat, leading to increased weight around the waist
2. Reduction in muscle mass and strength
3. Decreased energy levels
4. Irregularities in cholesterol levels

Elevated fracture risk Individuals affected by GHD undergo treatment with synthetic human GH administered through daily injections, prescribed by a medical professional.

• The prevalence of GHD is estimated to be between 1.8 and 2.9 per 10,000 children, with a higher frequency of diagnosis in boys.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: